VFC submits:
LaboPharm, Inc. (DDSS) announced on Wednesday that the US FDA has approved OLEPTRO, the company’s treatment for major depressive disorder [MDD] in adults. OLEPTRO is a once-daily formulation of trazodone and utilizes the LaboPharm’s controlled release technology, CONTRAMID.
According to the Wednesday morning press release, the company expects to have OLEPTRO available for prescription in the United States later this year.